Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ABBV-525 |
| Synonyms | |
| Therapy Description |
ABBV-525 inhibits MALT1 and leads to decreased CARD11-BCL10-MALT1 (CBM) signaling, potentially resulting in reduced immunosuppressionin the tumor microenvironment and inhibition of tumor cell growth (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ABBV-525 | ABBV 525|ABBV525 | MALT1 Inhibitor 6 | ABBV-525 inhibits MALT1 and leads to decreased CARD11-BCL10-MALT1 (CBM) signaling, potentially resulting in reduced immunosuppressionin the tumor microenvironment and inhibition of tumor cell growth (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05618028 | Phase I | ABBV-525 | Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets | Recruiting | USA | ISR | GBR | FRA | ESP | DEU | BEL | AUS | 1 |